D-Glutamate

D-Glutamate

SCHEMBL410241

[15NH2]C(CCC(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 1.00
GRM6 O15303 2/20 1.00
GRM7 Q14831 2/20 1.00
GRM4 Q14833 2/20 1.00
GRIN2D O15399 1/20 1.00
GRIN3B O60391 1/20 1.00
GSR P00390 1/20 1.00
CYP1A2 P05177 1/20 1.00
GRIK1 P39086 1/20 1.00
GRM5 P41594 1/20 1.00
GRIA1 P42261 1/20 1.00
GRIA2 P42262 1/20 1.00
GRIA3 P42263 1/20 1.00
SLC1A3 P43003 1/20 1.00
SLC1A2 P43004 1/20 1.00
SLC1A1 P43005 1/20 1.00
GRIA4 P48058 1/20 1.00
GRIN1 Q05586 1/20 1.00
GRIN2A Q12879 1/20 1.00
GRIK2 Q13002 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL1554237 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL2201 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL1332297 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL1330484 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL248800 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL931953 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
Glutamic Acid SCHEMBL5704264 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL1330824 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL17127348 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D
D-Glutamate SCHEMBL1332144 1.00 GRM8 (1.00) GRM8GRM6GRM7GRM4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12515210-B2 Regenerating the catalytic activity of a spent catalyst TOPSOE A/S (DK) 2026-01-06 US claimed
CN-114761637-B Non-rewet O/W (oil-in-water) emulsifying system for hydrophobic compounds 有机点击股份公司 2025-02-11 CN claimed
US-20250003152-A1 CITRIC ACID-CATALYSED CURRAN MODIFIED CARD BOARD MATERIALS CELLUCOMP LIMITED (GB) 2025-01-02 US claimed
US-12170350-B2 Lithium secondary battery including separator with ceramic layer having first ceramic particle bonded to second ceramic particle and manufacturing method the same HYUNDAI MOTOR COMPANY (KR) 2024-12-17 US claimed
EP-4426890-A1 CITRIC ACID-CATALYSED CURRAN MODIFIED CARD BOARD MATERIALS Cellucomp Limited (GB) 2024-09-11 EP claimed
US-20240269152-A1 NADES FORMULATIONS COMPRISING CANNABINOIDS CLEMSON UNIVERSITY 2024-08-15 US claimed
US-20240269141-A1 NADES FORMULATIONS COMPRISING PHARMACEUTICALS CLEMSON UNIVERSITY 2024-08-15 US claimed
WO-2024128542-A1 CUTTING OIL COMPOSITION 와이씨켐 주식회사 2024-06-20 WO claimed
CN-115124642-B Modified telechelic liquid rubber and preparation method thereof, wide-temperature-range low-heat-generation controllable viscosity rubber and preparation method thereof 株洲时代新材料科技股份有限公司 2024-03-29 CN claimed
EP-3677706-B1 COMPOSITIONS AND METHOD FOR PRE-TREATING SUBSTRATES FOR SUBSEQUENT FIXATION OF VAPOR PHASE CORROSION INHIBITORS EXCOR KORROSIONSFORSCHUNG GMBH (DE) 2024-03-06 EP claimed
US-20200170923-A1 USE OF POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBRIOUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR MOMENTIVE PERFORMANCE MATERIALS INC. 2020-06-04 US claimed
WO-2019178141-A1 ORGANIC METABOLITE COMPOSITIONS AND METHODS OF USE AS MITICIDES FOR HONEY BEES NIEMCZURA PAUL (US) 2019-09-19 WO claimed
US-9879293-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2018-01-30 US claimed
US-20160177354-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS SAFC, INC. 2016-06-23 US claimed
EP-2462115-B1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS INC (US) 2016-01-06 EP claimed
US-8703448-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2014-04-22 US claimed
EP-2462115-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS Infinity Pharmaceuticals, Inc. (US) 2012-06-13 EP claimed
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-04-05 US claimed
US-20110139713-A1 METHOD OF TREATMENT FOR WASTE WATER USING MICROBIALGROWTH PROMOTER NRP GROUP, INC. 2011-06-16 US claimed
WO-2011017551-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269152-A1 NADES FORMULATIONS COMPRISING CANNABINOIDS CNR2, CNR1, NNT GRM8 1016/4885GRM6 779/4885GRM7 1092/4885
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs TKT, TALDO1, BCHE GRM8 3695/4885GRM6 3773/4885GRM7 3798/4885
US-20240269141-A1 NADES FORMULATIONS COMPRISING PHARMACEUTICALS NNT, NADK, NAPRT GRM8 2568/4885GRM6 2228/4885GRM7 2439/4885
US-20200170923-A1 USE OF POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBRIOUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR ABAT, PCCA, FH GRM8 2934/4885GRM6 1965/4885GRM7 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.